‘Venetoclax’ at the IPO: Why Generics Need More than Patent Refusals
How much of a win is a patent rejection for domestic generics production? In this post, I discuss the specific points of IPO’s refusal as a continuation of Indian patent jurisprudence on Section 3(d), and why, irrespective of the essentiality of patent law to the discourse on generics, contrary to news reports, a single patent refusal alone is not sufficient in improving access to cancer therapies. The Making of a Blockbuster Drug Venetoclax is a blockbuster cancer drug jointly developed […]
‘Venetoclax’ at the IPO: Why Generics Need More than Patent Refusals Read More »









